Menu
PrevEp is a team of clinicians and scientists addressing essential needs for:
We are a US-based biotech company founded by world leaders in epilepsy research with decades of combined experience in the development of new therapies for epilepsy treatment and prevention. The founders combine deep expertise in basic science, drug development and clinical trials in epilepsy. The intimate collaboration between preclinical and clinical team members enables PrevEp to rapidly translate preclinical discoveries to clinical trials.
Click on picture for full bio
Chief Executive Officer, Co-founder
Chief Scientific Officer, Co-founder
Chief Operating Officer, Co-founder
Biomarker Development, Co-founder
Vice President, Product Development, Co-founder
Vice President, Clinical Trials, Co-founder
EPILEPSY PREVENTION BY NETWORK PHARMACOLOGY. Epileptogenesis is a complex process that is unlikely to be arrested by a single drug. PrevEp leverages recent discoveries in network pharmacology to design combination therapies that target a multitude of epileptogenic mechanisms, in the earliest stages after brain injury. Our lead combinations of safe FDA-cleared molecules are well-tolerated and have proven to block epileptogenesis in predictive rodent models.
ACUTE REPETITIVE SEIZURE TREATMENT BY INTRANASAL SELETRACETAM SPRAY. At-home treatments for acute repetitive seizures are benzodiazepines, which carry a risk of sedation and respiratory depression. PrevEp developed a novel nasal spray formulation of seletracetam, a highly potent anti-seizure drug, to enable safe and effective non-benzodiazepine acute repetitive seizure treatment.
NEONATAL SEIZURE TREATMENT BY INTRAVENOUS TOPIRAMATE. Neonatal seizures increase mortality and risk of lifelong brain damage. A safe and FDA-approved drug, topiramate suppresses neonatal seizures when other anti-seizure medications fail, but was not available in injectable form. PrevEp developed a novel intravenous topiramate formulation with orphan drug designation for neonatal seizure treatment
Our company concept is supported by leading epilepsy ambassadors
Professor of Neurology and Director of clinical trials at NYU Langone‘s Comprehensive Epilepsy Center; Chief Scientific Officer, Epilepsy Foundation
Professor of Neurology and Pharmacology, Director of Institute for Neurotherapeutics, University of California, Davis
Principal for EAG Pharma Consulting LLC; former SVP, Novartis Parmaceutical Coorporation
Professor of Neuroscience, Mario Negri Institute, Milan, Italy
Previous Vice President, Neurosciences Therapeutic Area, UCB Biopharma
SVP, strategic development, Neurelis
Chief Scientific Officer
co-founder
Vice President, Toxicology and Regulatory Affairs
Co-founder
Chief Development Officer
Co-founder
Detlev Boison, Ph.D. has >25 years translational epilepsy research experience. He is the PI of active antiepileptogenic drug discovery program, and identified a novel molecular target for antiepileptogenic therapy.
Biomarker Development
Co-founder
Alexander Rotenberg, M.D., Ph.D., Professor of Neurology (pediatric epilepsy) at Harvard Medical School, has >15 years of translational and clinical epilepsy experience. He is a leading basic researcher in preclinical post-traumatic epilepsy mechanisms and treatments, and a world leading clinician researcher in the use of transcranial magnetic stimulation (TMS) as a biomarker of brain excitability used in human antiseizure medication proof of concept study testing. He has been the PI of recent DoD and NIH PTE grants, and has discovered an anti-epileptogenic target and related biomarker that are incorporated into the PrevEp portfolio and strategy.
Vice President, Product Devel.
Co-founder
Matthias Koepp, M.D. has >30 years experience as a highly-cited and widely-published expert in epilepsy therapeutic product development. He is Professor of Neurology at the University College London (UCL) Queen Square Institute of Neurology, and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery (NHNN), London. In addition, he heads the Epilepsy Clinical Trials Unit at the NHNN, and Clinical Lead at the Epilepsy Society – UCL MRI-Unit. He has co-directed a recent, ongoing trial of prevention of epilepsy after stroke, the first Phase 3 study of prevention of post-stroke epilepsy ever done, the clinical design of which was based on his co-discovery of predictors of post-stroke epilepsy.
Vice Prsident, Clinical Trials, Co-Founder
